Progressive supranuclear palsy

Česká verzia

Authors: T. Bartošová ¹; J. Klempíř- ^{1 3}
Authors place of work: Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze ¹; Anatomický ústav, 1. LF UK v Praze ²; Evropská referenční síť pro vzácná neurologická onemocnění ³
Published in the journal: Cesk Slov Neurol N 2020; 83/116(6): 584-601
Category: Review Article
doi: https://doi.org/10.48095/cccsnn2020584

Summary

Progressive supranuclear palsy is a tauopathy belonging to atypical Parkinsonian syndromes. The main clinical symptoms include oculomotor dysfunctions, early postural instability, symmetrical hypokinetic-rigid syndrome with axial predominance and cognitive decline. The symptom variability and rate of progression depend on disease subtype. Diagnostics are based on clinical symptoms; MRI remains the most useful auxiliary method. The article is focused mainly on clinical perspectives and recent diagnostic approaches considering the latest recommendations. Symptomatic therapy remains of great importance as causal treatment is still lacking.

Keywords:

progressive supranuclear palsy – vertical gaze palsy – tauopathy – postural instability – parkinsonism – cognitive decline – Levodopa – amantadine

Zdroje

1. Ling H. Clinical approach to progressive supranuclear palsy. J Mov Disord 2016; 9 (1): 3–13. doi: 10.14802/jmd.15060.

2. Stamelou M, Giagkou N, Höglinger GU. One decade ago, one decade ahead in progressive supranuclear palsy. Mov Disord 2019; 34 (9): 1284–1293. doi: 10.1002/mds.27788.

3. McFarland, NR. Diagnostic approach to atypical parkinsonian syndromes. Continuum (Minneap Minn) 2016; 22 (4 Movement Disorders): 1117–1142. doi: 10.1212/CON.0000000000000348.

4. Wenning GK, Litvan I, Tolosa E. Milestones in atypical and secondary parkinsonisms. Mov Disord 2011; 26 (6): 1083–1095. doi: 10.1002/mds.23713.

5. Baba Y, Putzke JD, Whaley NR et al. Progressive supranuclear palsy: phenotypic sex differences in a clinical cohort. Mov Disord 2006; 21 (5): 689–692. doi: 10.1002/mds.20769.

6. Litvan I, Lees PS, Cunningham CR et al. Environmental and occupational risk factors for progressive supranuclear palsy: case-control study. Mov Disord 2016; 31 (5): 644–652. doi: 10.1002/mds.26512.

7. Steele JC, Capparos-Lefebvre D, Lees AJ et al. Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism-dementia complex and Guadeloupean parkinsonism. Parkinsonism Relat Disord 2002; 9 (1): 39–54. doi: 10.1016/s1353-8020 (02) 00043-3.

8. Shoeibi A, Olfati N, Litvan I. Frontrunner in translation: progressive supranuclear palsy. Front Neurol 2019; 10: 1125. doi: 10.3389/fneur.2019.01125.

9. Mimuro M, Yoshida M. Chameleons and mimics: Progressive supranuclear palsy and corticobasal degeneration. Neuropathology 2020; 40 (1): 57–67. doi: 10.1111/neup.12590.

10. Fujita K, Matsubura T, Miyamoto R et al. Co-morbidity of progressive supranuclear palsy and amyotrophic lateral sclerosis: a clinical-pathological case report. BMC Neurol 2019; 19 (1): 168. doi: 10.1186/s12883-019-1402-7.

11. Ando S, Kanazawa M, Onodera O. Progressive supranuclear palsy with predominant cerebellar ataxia. J Mov Disord 2019; 13 (1): 20–26. doi: 10.14802/jmd.19061.

12. Vogels T, Leuzy A, Cicognola C et al. Propagation of tau pathology: integrating insights from postmortem and in vivo studies. Biol Psychiatry 2019; 87 (9): 808–818. doi: 10.1016/j.biopsych.2019.09.019.

13. Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol 2017; 133 (5): 665–704. doi: 10.1007/s00401-017-1707-9.

14. Zhang CC, Xing A, Tan MS et al. The role of MAPT in neurodegenerative diseases: genetics, mechanisms and therapy. Mol Neurobiol 2016; 53 (7): 4893–4904. doi: 10.1007/s12035-015-9415-8.

15. Huang Y, Wu Z, Zhou B. Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity. Cell Mol Life Sci 2016; 73 (1): 1–21. doi: 10.1007/s00018-015-2042-8.

16. Pérez MJ, Jara C, Quintanilla RA. Contribution of tau pathology to mitochondrial impairment in neurodegeneration. Front Neurosci 2018; 12: 441. doi: 10.3389/fnins.2018.00441.

17. Colin M, Dujardin S, Schraen-Maschke S et al. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol 2020; 139 (1): 3–25. doi: 10.1007/s00401-019-02087-9.

18. Narasimhan S, Changolkar L, Riddle DM et al. Human tau pathology transmits glial tau aggregates in the absence of neuronal tau. J Exp Med 2020; 217 (2): e20190783. doi: 10.1084/jem.20190783.

19. Komori T. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick‘s disease. Brain Pathol 1999; 9 (4): 663–679. doi: 10.1111/j.1750-3639.1999.tb00549.x.

20. Ling H, De Silva R, Massey LA et al. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant. Neuropathol Appl Neurobiol 2014; 40 (2): 149–163. doi: 10.1111/nan.12037.

21. Sakurai K, Tokumaru AM, Shimoji K et al. Beyond the midbrain atrophy: wide spectrum of structural MRI finding in cases of pathologically proven progressive supranuclear palsy. Neuroradiology 2017; 59 (5): 431–443. doi: 10.1007/s00234-017-1812-4.

22. Oyanagi K, Tsuchiya K, Yamazaki M et al. Substantia nigra in progressive supranuclear palsy, corticobasal degeneration, and parkinsonism-dementia complex of Guam: specific pathological features. J Neuropathol Exp Neurol 2001; 60 (4): 393–402. doi: 10.1093/jnen/60.4.393.

23. MacLaren DA, Ljungberg TL, Griffin ME et al. Pedunculopontine tegmentum cholinergic loss leads to a progressive decline in motor abilities and neuropathological changes resembling progressive supranuclear palsy. Eur J Neurosci 2018; 48 (12): 3477–3497. doi: 10.1111/ejn.14212.

24. Landwehrmeyer B, Palacios JM. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm Suppl 1994; 42: 229–246. doi: 10.1007/978-3-7091-6641-3_18.

25. Respondek G, Kurz C, Arzberger T et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord 2017; 32 (7): 995–1005. doi: 10.1002/mds.27034.

26. Schirinzi T, Sancesario GM, Di Lazzaro G et al. Clinical value of CSF amyloid-beta-42 and tau proteins in progressive supranuclear palsy. J Neural Transm (Vienna) 2018; 125 (9): 1373–1379. doi: 10.1007/s00702-018-1893-1.

27. Wang SY, Chen W, Xu W et al. Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: a systematic review and meta-analysis. J Alzheimers Dis 2019; 72 (4): 1353–1361. doi: 10.3233/JAD-190615.

28. Donker Kaat L, Meeter LH, Zheng Chiu W et al. Serum neurofilament light chain in progressive supranuclear palsy. Parkinsonism Relat Disord 2018; 56: 98–101. doi: 10.1016/j.parkreldis.2018.06.018.

29. Kataoka H, Sugie K. Serum adiponectin levels between patients with Parkinson‘s disease and those with PSP. Neurol Sci 2020; 41 (5): 1125–1131. doi: 10.1007/s10072-019-04216-4.

30. Eraslan C, Acaer A, Guneyli S et al. MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson‘s disease and multiple system atrophy. Neurol Res 2019; 41 (2): 110–117. doi: 10.1080/01616412.2018.1541115.

31. Mueller C, Hussl A, Krismer F et al. The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Parkinsonism Relat Disord 2018; 54: 90–94. doi: 10.1016/j.parkreldis.2018.04.005.

32. Mostile G, Nicoletti A, Cicero CE et al. Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism. Neurol Sci 2016; 37 (4): 591–595. doi: 10.1007/s10072-016-2489-x.

33. Quattrone A, Morelli M, Nigro S et al. A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson‘s disease. Parkinsonism Relat Disord, 2018. 54: 3–8. doi: 10.1016/j.parkreldis.2018.07.016.

34. Constantinides VC, Paraskevas GP, Stamboulis E et al. Simple linear brainstem MRI measurements in the differential diagnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy. Neurol Sci 2018; 39 (2): 359–364. doi: 10.1007/s10072-017-3212-2.

35. Quattrone A, Morelli M, Quattrone A et al. Magnetic resonance parkinsonism index for evaluating disease progression rate in progressive supranuclear palsy: a longitudinal 2-year study. Parkinsonism Relat Disord 2020; 72: 1–6. doi: 10.1016/j.parkreldis.2020.01.019.

36. Oktay C, Özkaynak SS, Eseroğlu E et al. Contribution of the mesencephalon indices to differential diagnosis of parkinsonian disorders. Can Assoc Radiol J 2020; 71 (1): 100–109. doi: 10.1177/0846537119888411.

37. Mitchell T, Archer DB, Chu WT et al. Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in parkinsonism. Hum Brain Mapp 2019; 40 (17): 5094–5107. doi: 10.1002/hbm.24760.

38. Richter D, Katsanos AH, Schroeder C et al. Lentiform nucleus hyperechogenicity in parkinsonian syndromes: a systematic review and meta-analysis with consideration of molecular pathology. Cells 2019; 9 (1): 2. doi: 10.3390/cells9010002.

39. Alonso-Canovas A, Ferrairó JI, Martínez-Torres I et al. Transcranial sonography in atypical parkinsonism: How reliable is it in real clinical practice? A multicentre comprehensive study. Parkinsonism Relat Disord, 2019. 68: 40–45. doi: 10.1016/j.parkreldis.2019.09.032.

40. Vintonyak O, Gorges M, Müller HP et al. Patterns of eye movement impairment correlate with regional brain atrophy in neurodegenerative parkinsonism. Neurodegener Dis 2017; 17 (4–5): 117–126. doi: 10.1159/000454880.

41. Panyakaew P, Anan C, Bhidayasiri R. Posturographic abnormalities in ambulatory atypical parkinsonian disorders: Differentiating characteristics. Parkinsonism Relat Disord 2019; 66: 94–99. doi: 10.1016/j.parkreldis.2019.07.016.

42. Ondo W, Warrior D, Overby A et al. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson‘s disease and healthy controls. Arch Neurol 2000; 57 (10): 1464–1469. doi: 10.1001/archneur.57.10.1464.

43. Dale ML, Horak FB, Wright WG et al. Impaired perception of surface tilt in progressive supranuclear palsy. PLoS One 2017; 12 (3): e0173351. doi: 10.1371/journal.pone.0173351.

44. Kammermeier S, Maierbeck K, Dietrich L et al. Qualitative postural control differences in idiopathic Parkinson‘s disease vs. progressive supranuclear palsy with dynamic-on-static platform tilt. Clin Neurophysiol 2018; 129 (6): 1137–1147. doi: 10.1016/j.clinph.2018.03.002.

45. Tykalova T, Rusz J, Klempir J et al. Distinct patterns of imprecise consonant articulation among Parkinson‘s disease, progressive supranuclear palsy and multiple system atrophy. Brain Lang 2017; 165: 1–9. doi: 10.1016/j.bandl.2016.11.005.

46. de Yébenes JG, Sarasa JL, Daniel SE et al. Familial progressive supranuclear palsy. Description of a pedigree and review of the literature. Brain 1995; 118 (Pt 5): 1095–1103. doi: 10.1093/brain/118.5.1095.

47. Ali F, Josephs K. The diagnosis of progressive supranuclear palsy: current opinions and challenges. Expert Rev Neurother 2018; 18 (7): 603–616. doi: 10.1080/14737175.2018.1489241.

48. Im SY, Kim YE, Kim YJ. Genetics of progressive supranuclear palsy. J Mov Disord 2015; 8 (3): 122–129. doi: 10.14802/jmd.15033.

49. Ingelsson M, Ramasamy K, Russ C et al. Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol 2007; 114 (5): 471–479. doi: 10.1007/s00401-007-0280-z.

50. Borroni B et al. Genetic bases of progressive supranuclear palsy: the MAPT tau disease. Curr Med Chem 2011; 18 (17): 2655–2660. doi: 10.2174/092986711795933722.

51. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333–359. doi: 10.1001/archneur.1964.00460160003001.

52. Kammermeier S, Dietrich L, Maierbeck K et al. Postural stabilization differences in idiopathic parkinson‘s disease and progressive supranuclear palsy during self-triggered fast forward weight lifting. Front Neurol 2017; 8: 743. doi: 10.3389/fneur.2017.00743.

53. Hoglinger GU, Respondek G, Stamelou M et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord 2017; 32 (6): 853–864. doi: 10.1002/mds.26987.

54. Burn DJ, Lees AJ. Progressive supranuclear palsy: where are we now? Lancet Neurol 2002; 1 (6): 359–369. doi: 10.1016/s1474-4422 (02) 00161-8.

55. Cronin T, Arshad Q, Seemungal BM. Vestibular deficits in neurodegenerative disorders: balance, dizziness, and spatial disorientation. Front Neurol 2017; 8: 538. doi: 10.3389/fneur.2017.00538.

56. Fujioka S, Algom AA, Murray ME et al. Tremor in progressive supranuclear palsy. Parkinsonism Relat Disord 2016; 27: 93–97. doi: 10.1016/j.parkreldis.2016.03.015.

57. Anagnostou E, Karavasilis E, Potiri I et al. A cortical substrate for square-wave jerks in progressive supranuclear palsy. J Clin Neurol 2020; 16 (1): 37–45. doi: 10.3988/jcn.2020.16.1.37.

58. Quinn N. The „round the houses“ sign in progressive supranuclear palsy. Ann Neurol 1996; 40 (6): 951. doi: 10.1002/ana.410400630.

59. Matsumoto H, Inaba T, Kakumoto T et al. Progressive supranuclear palsy with wall-eyed bilateral internuclear ophthalmoplegia syndrome: authors‘ second case. Case Rep Neurol 2019; 11 (2): 205–208. doi: 10.1159/000501394.

60. Batla A, Nehru R, Vijay T. Vertical wrinkling of the forehead or Procerus sign in progressive supranuclear palsy. J Neurol Sci 2010; 298 (1–2): 148–149. doi: 10.1016/j.jns.2010.08.010.

61. Marsili L, Bologna M, Kjovic M et al. Dystonia in atypical parkinsonian disorders. Parkinsonism Relat Disord 2019; 66: 25–33. doi: 10.1016/j.parkreldis.2019.07.030.

62. Boxer AL, Lang AE, Grossman M et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014; 13 (7): 676–685. doi: 10.1016/S1474-4422 (14) 70088-2.

63. Kim JH, McCann CM. Communication impairments in people with progressive supranuclear palsy: a tutorial. J Commun Disord 2015; 56: 76–87. doi: 10.1016/j.jcomdis.2015.06.002.

64. Skodda S, Visser W, Schlegel U. Acoustical analysis of speech in progressive supranuclear palsy. J Voice 2011; 25 (6): 725–731. doi: 10.1016/j.jvoice.2010.01.002.

65. Clark HM, Stierwalt JA, Tosakulwong N et al. Dysphagia in progressive supranuclear palsy. Dysphagia 2020; 35 (4): 667–676. doi: 10.1007/s00455-019-10073-2.

66. Iwasaki Y, Yoshida M, Hashizume Y et al. Widespread spinal cord involvement in progressive supranuclear palsy. Neuropathology 2007; 27 (4): 331–340. doi: 10.1111/j.1440-1789.2007.00787.x.

67. Vitaliani R, Scaravilli T, Egarter-Vigl E et al. The pathology of the spinal cord in progressive supranuclear palsy. J Neuropathol Exp Neurol 2002; 61 (3): 268–274. doi: 10.1093/jnen/61.3.268.

68. Gawel M, Jamrozik Z, Szmidt-Salkowska E et al. Electrophysiological features of lower motor neuron involvement in progressive supranuclear palsy. J Neurol Sci 2013; 324 (1–2): 136–139.

69. Nomura T, Inoue Y, Takigawa H et al. Comparison of REM sleep behaviour disorder variables between patients with progressive supranuclear palsy and those with Parkinson‘s disease. Parkinsonism Relat Disord 2012; 18 (4): 394–396. doi: 10.1016/j.parkreldis.2011.10.018.

70. Walsh CM, Ruoff L, Walker K et al. Sleepless night and day, the plight of progressive supranuclear palsy. Sleep 2017; 40 (11), zsx154. doi: 10.1093/sleep/zsx154.

71. Yousaf T, Pagano G, Wilson H et al. Neuroimaging of sleep disturbances in movement disorders. Front Neurol 2018; 9: 767. doi: 10.3389/fneur.2018.00767.

72. Oliveira MC, Ling H, Lees AJ et al. Association of autonomic symptoms with disease progression and survival in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2019; 90 (5): 555–561. doi: 10.1136/jnnp-2018-319374.

73. Yamamoto T, Tateno F, Sakakibara R et al. Urinary dysfunction in progressive supranuclear palsy compared with other parkinsonian disorders. PLoS One 2016; 11 (2): e0149278. doi: 10.1371/journal.pone.0149278.

74. Kim KJ, Jeong SJ, Kim JM. Neurogenic bladder in progressive supranuclear palsy: a comparison with Parkinson‘s disease and multiple system atrophy. Neurourol Urodyn 2018; 37 (5): 1724–1730. doi: 10.1002/nau.23496.

75. Sulena, Gupta D, Sharma AK et al. Clinical profile of cognitive decline in patients with parkinson‘s disease, progressive supranuclear palsy, and multiple system atrophy. J Neurosci Rural Pract 2017; 8 (4): 562–568. doi: 10.4103/jnrp.jnrp_154_17.

76. Rittman T, Coyle-Gilchrist IT, Rowe JB. Managing cognition in progressive supranuclear palsy. Neurodegener Dis Manag 2016; 6 (6): 499–508. doi: 10.2217/nmt-2016-0027.

77. Burrell JR, Hodges JR, Rowe JB. Cognition in corticobasal syndrome and progressive supranuclear palsy: a review. Mov Disord 2014; 29 (5): 684–693. doi: 10.1002/mds.25872.

78. Smith DT, Archibald N. Spatial working memory in progressive supranuclear palsy. Cortex 2020; 122: 115–122. doi: 10.1016/j.cortex.2018.07.004.

79. Santangelo G, Cuoco S, Pellecchia MT et al. Comparative cognitive and neuropsychiatric profiles between Parkinson‘s disease, multiple system atrophy and progressive supranuclear palsy. J Neurol 2018; 265 (11): 2602–2613. doi: 10.1007/s00415-018-9038-x.

80. Sitek EJ, Wieczorek D, Konkel A et al. The pattern of verbal, visuospatial and procedural learning in Richardson variant of progressive supranuclear palsy in comparison to Parkinson‘s disease. Psychiatr Pol 2017; 51 (4): 647–659. doi: 10.12740/PP/OnlineFirst/62804.

81. Barker MS, Nelson NL, O’Sullivan JD et al. Energization and spoken language production: Evidence from progressive supranuclear palsy. Neuropsychologia 2018; 119: 349–362. doi: 10.1016/j.neuropsychologia.2018.09.004.

82. Robinson GA, Spooner D, Harrison WJ. Frontal dynamic aphasia in progressive supranuclear palsy: Distinguishing between generation and fluent sequencing of novel thoughts. Neuropsychologia 2015; 77: 62–75. doi: 10.1016/j.neuropsychologia.2015.08.001.

83. Sakae N, Josephs KA, Litvan I et al. Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. Mov Disord 2019; 34 (11): 1655–1662. doi: 10.1002/mds.27816.

84. Fiorenzato E, Antonini A, Camparini V et al. Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson‘s disease. J Neural Transm (Vienna) 2019; 126 (11): 1437–1445. doi: 10.1007/s00702-019-02065-1.

85. Lansdall CJ, Coyle-Gilchrist IT, Simon Jones P et al. Apathy and impulsivity in frontotemporal lobar degeneration syndromes. Brain 2017, 140 (6): 1792–1807. doi: 10.1093/brain/awx101.

86. Schrag A, Sheikh S, Quinn NP et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord 2010; 25 (8): 1077–1081. doi: 10.1002/mds.22794.

87. Belvisi D, Berardelli I, Suppa A et al. Neuropsychiatric disturbances in atypical parkinsonian disorders. Neuropsychiatr Dis Treat 2018; 14: 2643–2656. doi: 10.2147/NDT.S178263.

88. Litvan I, Agid Y, Calne D et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47 (1): 1–9. doi: 10.1212/wnl.47.1.1.

89. Grimm MJ, Respondek G, Stamelou M et al. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord 2019; 34 (8): 1228–1232. doi: 10.1002/mds.27666.

90. Armstrong MJ. Progressive supranuclear palsy: an update. Curr Neurol Neurosci Rep 2018; 18 (3): 12. doi: 10.1007/s11910-018-0819-5.

91. Lopez G, Bayulkem K, Hallett M. Progressive supranuclear palsy (PSP): Richardson syndrome and other PSP variants. Acta Neurol Scand 2016; 134 (4): 242–249. doi: 10.1111/ane.12546.

92. Litvan I, Mangone CA, McKee A et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry 1996; 60 (6): 615–620. doi: 10.1136/jnnp.60.6.615.

93. Arena JE, Weigand SD, Whitwell JL et al. Progressive supranuclear palsy: progression and survival. J Neurol 2016; 263 (2): 380–389. doi: 10.1007/s00415-015-7990-2.

94. Respondek G, Höglinger GU. The phenotypic spectrum of progressive supranuclear palsy. Parkinsonism Relat Disord 2016; 22 (Suppl 1): S34–36. doi: 10.1016/j.parkreldis.2015.09.041.

95. Albert ML, Feldman RG, Willis AL. The “subcortical dementia” of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 1974; 37 (2): 121–130. doi: 10.1136/jnnp.37.2.121.

96. Respondek G, Stamelou M, Kurz C et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014; 29 (14): 1758–1766. doi: 10.1002/mds.26054.

97. Josephs KA, Duffy JR. Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy. Curr Opin Neurol 2008; 21 (6): 688–692. doi: 10.1097/WCO.0b013e3283168ddd.

98. Dickson DW, Ahmed Z, Algom AA et al. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol 2010; 23 (4): 394–400. doi: 10.1097/WCO.0b013e32833be924.

99. Santos-Santos MA, Mandelli ML, Binney RJ et al. Features of patients with nonfluent/agrammatic primary progressive aphasia with underlying progressive supranuclear palsy pathology or corticobasal degeneration. JAMA Neurol 2016; 73 (6): 733–742. doi: 10.1001/jamaneurol.2016.0412.

100. Josephs KA, Katsuse O, Beccano-Kelly DA et al. Atypical progressive supranuclear palsy with corticospinal tract degeneration. J Neuropathol Exp Neurol 2006; 65 (4): 396–405. doi: 10.1097/01.jnen.0000218446.38158.61.

101. Storey K, Johanidesová S, Matěj R et al. FTLD-TDP and progressive supranuclear palsy in comorbidity-a report of two cases with different clinical presentations. Neurocase 2017; 23 (1): 5–11. doi: 10.1080/13554794.2016.1264058.

102. Kertesz A, Finger R, Murell J et al. Progressive supranuclear palsy in a family with TDP-43 pathology. Neurocase 2015; 21 (2): 178–84. doi: 10.1080/13554794.2013.878729.

103. Menšíková K, Matěj R, Tučková L et al. Progressive supranuclear palsy phenotype mimicking synucleinopathies. J Neurol Sci 2013; 329 (1–2): 34–37.

104. Boxer AL, Yu JT, Golbe LI et al. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 2017; 16 (7): 552–563. doi: 10.1016/S1474-4422 (17) 30157-6.

105. Jabbari E, Holland N, Chelban V et al. Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome. JAMA Neurol 2020; 77 (3): 377–388. doi: 10.1001/jamaneurol.2019.4347.

106. Nakashima H, Terada S, Ishizu H et al. An autopsied case of dementia with Lewy bodies with supranuclear gaze palsy. Neurol Res 2003; 25 (5): 533–537. doi: 10.1179/016164103101201788.

107. Constantinides VC, Paraskevas GP, Velonakis G et al. Midbrain morphology in idiopathic normal pressure hydrocephalus: a progressive supranuclear palsy mimic. Acta Neurol Scand 2020; 141 (4): 328–334. doi: 10.1111/ane.13205.

108. Lloyd-Smith Sequeira A, Rizzo JR, Rucker JC. Clinical approach to supranuclear brainstem saccadic gaze palsies. Front Neurol 2017; 8: 429. doi: 10.3389/fneur. 2017.00429.

109. Salsano E, Umeh C, Rufa A et al. Vertical supranuclear gaze palsy in Niemann-Pick type C disease. Neurol Sci 2012; 33 (6): 1225–1232. doi: 10.1007/s10072-012-1155-1.

110. Kresojević N, Mandić-Stojmenović G, Dobričić V et al. Very late-onset Niemann-Pick type C disease: example of progressive supranuclear palsy look-alike disorder. Mov Disord Clin Pract 2020; 7 (2): 211–214. doi: 10.1002/mdc3.12892.

111. Nadjar Y, Hütter-Moncada AL, Latour P et al. Adult Niemann-Pick disease type C in France: clinical phenotypes and long-term miglustat treatment effect. Orphanet J Rare Dis 2018; 13 (1): 175. doi: 10.1186/s13023-018-0913-4.

112. Bremova-Ertl T, Schiffmann R, Patterson MC et al. Oculomotor and vestibular findings in Gaucher disease type 3 and their correlation with neurological findings. Front Neurol 2017; 8: 711. doi: 10.3389/fneur.2017.00711.

113. Modreanu R, Özdemir G, Buhmann C et al. Levodopa-induced dystonia in a patient with possible progressive supranuclear palsy with progressive gait freezing. J Neurol Sci 2018; 388: 139–140. doi: 10.1016/j.jns.2018.03.023.

114. Vasta R, Nicoletti A, Mostile G et al. Side effects induced by the acute levodopa challenge in Parkinson‘s disease and atypical parkinsonisms. PLoS One 2017; 12 (2): e0172145. doi: 10.1371/journal.pone.0172145.

115. Hiller A, Murchison C, Nichols J et al. The effects of amantadine on the progression of progressive supranuclear palsy (psp). [online]. Available from: https: //n.neurology.org/content/90/15_Supplement/P6.068

116. Stamelou M, Hoglinger G. A review of treatment options for progressive supranuclear palsy. CNS Drugs 2016; 30 (7): 629–636. doi: 10.1007/s40263-016-0347-2.

117. Kompoliti K, Goetz CG, Litvan I et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998; 55 (8): 1099–1102. doi: 10.1001/archneur.55.8.1099.

118. Engel PA. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J Am Geriatr Soc 1996; 44 (9): 1072–1074. doi: 10.1111/j.1532-5415.1996.tb02940.x.

119. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med 1999; 341 (7): 543–544. doi: 10.1046/j.1468-1331.2002.0354g.x.

120. Zampieri C, Di Fabio RP. Balance and eye movement training to improve gait in people with progressive supranuclear palsy: quasi-randomized clinical trial. Phys Ther 2008; 88 (12): 1460–1473. doi: 10.2522/ptj. 20070302.

121. Dash SK. Zolpidem in progressive supranuclear palsy. Case Rep Neurol Med 2013; 2013: 250865. doi: 10.1046/j.1468-1331.2002.0354g.x.

122. Chang AY, Weirich E. Trial of zolpidem, eszopiclone, and other GABA agonists in a patient with progressive supranuclear palsy. Case Rep Med 2014; 2014: 107064. doi: 10.1155/2014/107064.

123. Cooper AD, Josephs KA. Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration: a prospective study. Parkinsonism Relat Disord 2009; 15 (1): 59–61. doi: 10.1016/j.parkreldis.2008.01.011.

124. Asociace klinických logopedů České republiky. [online]. Dostupné z URL: https: //www.klinickalogopedie.cz/.

125. SKVIMP. Společnost klinické výživy a intenzivní metabolické péče. [online]. Dostupné z URL: http: //www.skvimp.cz/.

126. Intiso D, Bartolo M, Santamato A et al. The role of rehabilitation in patients with progressive supranuclear palsy: a narrative review. PM R 2018, 10 (6): 636–645. doi: 10.1016/j.pmrj.2017.12.011.

127. Slade SC, Finkelstein DI, McGinley JL et al. Exercise and physical activity for people with progressive supranuclear palsy: a systematic review. Clin Rehabil 2020; 34 (1): 23–33. doi: 10.1177/0269215519877235.

128. Tilley E, McLoughlin J, Koblar SA et al. Effectiveness of allied health therapy in the symptomatic management of progressive supranuclear palsy: a systematic review. JBI Database System Rev Implement Rep 2016; 14 (6): 148–95. doi: 10.11124/JBISRIR-2016-2002352.

129. Phokaewvarangkul O, Bhidayasiri R. How to spot ocular abnormalities in progressive supranuclear palsy? A practical review. Transl Neurodegener 2019; 8: 20. doi: 10.1186/s40035-019-0160-1.

130. Wiblin L, Lee M, Burn D. Palliative care and its emerging role in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 2017; 34: 7–14.

131. Spolek pro atypické Parkinsonské syndromy. [online]. Dostupné z URL: https: //aps.estranky.cz/.

132. Brown FS, Rowe JB, Passamonti L et al. Falls in progressive supranuclear palsy. Mov Disord Clin Pract2020; 7 (1): 16–24. doi: 10.1016/j.parkreldis.2016.10.013.

133. Apetauerova D, Scala SA, Hamill RW et al. CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm 2016; 3 (5): e266. doi: 10.1212/NXI. 0000000000000266.

134. Chen Z, Chen JA, Shatunov A et al. Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy. Mov Disord 2019; 34 (7): 1049–1059. doi: 10.1002/mds.27702.

135. Boxer AL, Qureshi I, Ahlijanian M et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol 2019; 18 (6): 549–558. doi: 10.1016/S1474-4422 (19) 30139-5.